Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAVZ1F)

Drug Name

NPC-567 Drug Info

Synonyms

Npc-567; Npc 567; Arg-3-hyp-7-phe-bradykinin; UNII-DV64B0PLEH; 109333-26-8; Bradykinin, arg-hyp(3)-phe(7)-; DV64B0PLEH; Bradykinin, arg(0)-hyp(3)-phe(7)-; CHEMBL446325; CHEBI:73294; arg(0)-hyp(3)-phe(7)-bradykinin; Bradykinin, arginyl-hydroxyprolyl(3)-phenylalanine(7)-; [D-Arg(0),Hyp(3),D-Phe(7)]bradykinin; Bradykinin, N2-D-arginyl-3-(trans-4-hydroxy-L-proline)-7-D-phenylalanine-

Indication

Disease Entry	ICD 11	Status	REF
Rhinitis	FA20	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 119343
ChEBI ID: CHEBI:73294
CAS Number: CAS 109333-26-8
TTD Drug ID: DMAVZ1F

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting B2 bradykinin receptor (BDKRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Icatibant	DMQPTOZ	Hereditary angioedema	4A00.14	Approved	[3]
Fasitibant chloride	DM563NC	Osteoarthritis	FA00-FA05	Phase 2	[4]
DELTIBANT	DM5CB8U	Sepsis	1G40-1G41	Phase 2	[5]
Anatibant	DMG7IEN	Traumatic brain injury	NA07.Z	Phase 2	[6]
DM199	DM0157T	Cerebral ischemia	8B11	Phase 2	[7]
BRADYKININ	DM4R6UV	N. A.	N. A.	Phase 1	[8]
Labradimil	DMSFL76	Brain cancer	2A00	Discontinued in Phase 2	[9]
NPC-17731	DMGVIZY	Asthma	CA23	Terminated	[10]
JSM-10292	DMU5TGC	Pain	MG30-MG3Z	Terminated	[11]
CP-0597	DMS23JX	Asthma	CA23	Terminated	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B2 bradykinin receptor (BDKRB2)	TTGY8IW	BKRB2_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 676).
2	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain... J Med Chem. 2008 Nov 27;51(22):7094-8.
3	Bradykinin receptor antagonists--a review of the patent literature 2005-2008. Expert Opin Ther Pat. 2009 Jul;19(7):919-41.
4	Fasitibant chloride, a kinin B receptor antagonist, and dexamethasone interact to inhibit carrageenan-induced inflammatory arthritis in rats. Br J Pharmacol. 2012 Jun;166(4):1403-10.
5	CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992;38 ( Pt 3):413-20.
6	Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome. Crit Care Med. 2009 Jul;37(7):2228-34.
7	Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors. Pharmacol Res Perspect. 2015 Mar;3(2):e00119.
8	Synthesis and biological evaluation of bradykinin B(1)/B(2) and selective B(1) receptor antagonists. J Med Chem. 2000 Jun 15;43(12):2382-6.
9	Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med. 2009 May 13;7:33.
10	Antinociceptive profile of the pseudopeptide B2 bradykinin receptor antagonist NPC 18688 in mice. Br J Pharmacol. 1996 Feb;117(3):552-558.
11	Binding characteristics of [3H]-JSM10292: a new cell membrane-permeant non-peptide bradykinin B2 receptor antagonist. Br J Pharmacol. 2012 Oct;167(4):839-53.
12	CP-0597, a selective bradykinin B2 receptor antagonist, inhibits brain injury in a rat model of reversible middle cerebral artery occlusion. Stroke. 1997 Jul;28(7):1430-6.